Good long-term outcome of Budd-Chiari syndrome with a step-wise management

Hepatology

Volumn 57, Issue 5, 2013, Pages 1962-1968

  Seijo, Susana ^a   Plessier, Aurelie ^b   Hoekstra, Jildou ^c   Dell'Era, Alessandra ^d,e   Mandair, Dalvinder ^f   Rifai, Kinan ^g   Trebicka, Jonel ^h   Morard, Isabelle ⁱ   Lasser, Luc ^j   Abraldes, Juan G ^a   Darwish Murad, Sarwa ^c   Heller, Jörg ^h   Hadengue, Antoine ⁱ   Primignani, Massimo ^k   Elias, Elwyn ^f   Janssen, Harry L A ^c   Valla, Dominique C ^b   Garcia Pagan, Juan Carlos ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^k FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN;

ADOLESCENT; ADULT; AGED; ANGIOPLASTY; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BUDD CHIARI SYNDROME; FEMALE; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; ROTTERDAM SCORE; SURVIVAL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BUDD-CHIARI SYNDROME; COHORT STUDIES; DISEASE MANAGEMENT; EUROPE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOLYTIC THERAPY; YOUNG ADULT;

EID: 84876697522     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26306     Document Type: Article

References (22)

1. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38: 364-371.
2. Ludwig J, Hashimoto E, McGill DB, van Heerden JA. Classification of hepatic venous outflow obstruction: ambiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc 1990; 65: 51-55.
3. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. HEPATOLOGY 2003; 38: 793-803.
4. Darwish MS, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151: 167-175.
5. Valla DC. Hepatic vein thrombosis (Budd-Chiari syndrome). Semin Liver Dis 2002; 22: 5-14.
6. Garcia-Pagan JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008; 135: 808-815.
7. Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. HEPATOLOGY 1999; 30: 84-89.
8. Valla DC. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004; 19: S204-S211.
9. Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. HEPATOLOGY 2004; 39: 500-508.
10. Plessier A, Sibert A, Consigny Y, Hakime A, Zappa M, Denninger MH, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. HEPATOLOGY 2006; 44: 1308-1316.
11. Hadengue A, Poliquin M, Vilgrain V, Belghiti J, Degott C, Erlinger S, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology 1994; 106: 1042-1047.
12. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-664.
13. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. HEPATOLOGY 2000; 31: 864-871.
14. Langlet P, Escolano S, Valla D, Coste-Zeitoun D, Denie C, Mallet A, et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol 2003; 39: 496-501.
15. Rautou PE, Douarin L, Denninger MH, Escolano S, Lebrec D, Moreau R, et al. Bleeding in patients with Budd-Chiari syndrome. J Hepatol 2011; 54: 56-63.
16. Han G, Qi X, Zhang W, He C, Yin Z, Wang J, et al. Percutaneous recanalization for Budd-Chiari syndrome: An 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Hepatol 2012; 266: 657-667.
17. Orloff MJ, Isenberg JI, Wheeler HO, Daily PO, Girard B. Budd-Chiari syndrome revisited: 38 years' experience with surgical portal decompression. J Gastrointest Surg 2012; 16: 286-300.
18. Montano-Loza AJ, Tandon P, Kneteman N, Bailey R, Bain VG. Rotterdam score predicts early mortality in Budd-Chiari syndrome, and surgical shunting prolongs transplant-free survival. Aliment Pharmacol Ther 2009; 30: 1060-1069.
19. Hemming AW, Langer B, Greig P, Taylor BR, Adams R, Heathcote EJ. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg 1996; 171: 176-180.
20. Panis Y, Belghiti J, Valla D, Benhamou JP, Fekete F. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery 1994; 115: 276-281.
21. Langlet P, Valla D. Is surgical portosystemic shunt the treatment of choice in Budd-Chiari syndrome? Acta Gastroenterol Belg 2002; 65: 155-160.
22. Bachet JB, Condat B, Hagege H, Plessier A, Consigny Y, Belghiti J, et al. Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. J Hepatol 2007; 46: 60-68.